Get the Stockscreener App
2.41
4.78%
0.11
After Hours:
2.44
0.03
+1.24%
Xbiotech Inc stock is traded at $2.41, with a volume of 90,324.
It is up +4.78% in the last 24 hours and up +1.69% over the past month.
XBiotech Inc is a biopharmaceutical company that discovers and develops True Human monoclonal antibodies derived from human donors to replicate the human immune response in the treatment of various diseases. It has developed a pipeline of product candidates using True Human antibodies targeting both inflammatory and infectious diseases. The company's developement pipeline comprises: Natrunix, an antibody targeting IL-1a in oncology (pancreatic cancer), a clinical stage therapeutic for Methicillin Resistant Staphylococcus aureus (MRSA), and several pre-clinical stage therapeutics, including: an oral delivery antibody therapeutic for colon infection by C. difficile; an injectable therapy for varicella zoster (adult chicken pox), the causative agent for shingles; and an influenza therapy.
See More
Previous Close:
$2.30
Open:
$2.32
24h Volume:
90,324
Relative Volume:
3.22
Market Cap:
$73.48M
Revenue:
$300.00K
Net Income/Loss:
$-40.16M
P/E Ratio:
-1.8294
EPS:
-1.3174
Net Cash Flow:
$-42.36M
1W Performance:
+3.43%
1M Performance:
+1.69%
6M Performance:
-4.74%
1Y Performance:
-24.21%
1-Day Range:
$2.31
$2.4352
1-Week Range:
$2.30
$2.4352
52-Week Range:
$2.09
$3.61
Xbiotech Inc Stock (XBIT) Company Profile
Name
Xbiotech Inc
Sector
Industry
Phone
512-386-2900
Address
5217 WINNEBAGO LANE, AUSTIN, TX
Compare XBIT vs VRTX, REGN, ARGX, ALNY, RVMD
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
XBIT
Xbiotech Inc
|
2.41 | 70.12M | 300.00K | -40.16M | -42.36M | -1.3174 |
VRTX
Vertex Pharmaceuticals Inc
|
529.59 | 126.07B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
649.81 | 65.37B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
916.80 | 57.70B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
313.04 | 40.19B | 4.29B | 577.22M | 641.34M | 4.2086 |
RVMD
Revolution Medicines Inc
|
189.99 | 39.82B | 742.00K | -1.37B | -1.07B | -7.0731 |
Xbiotech Inc Stock (XBIT) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jun-14-19 | Initiated | Piper Jaffray | Overweight |
| Apr-21-17 | Downgrade | Noble Financial | Buy → Hold |
| Jun-28-16 | Reiterated | Noble Financial | Buy |
Xbiotech Inc Stock (XBIT) Latest News
XBiotech, Inc. Actuals & Estimates (SWB:4XB) - TradingView
XBiotech, Inc. Actuals & Estimates (LS:A14QF1) - TradingView
XBiotech, Inc. Actuals & Estimates (FWB:4XB) - TradingView
Price to earnings forward of XBiotech Inc. – NASDAQ:XBIT - TradingView
XBiotech, Inc. Actuals & Estimates (MUN:4XB) - TradingView
XBiotech, Inc. Actuals & Estimates (NASDAQ:XBIT) - TradingView
Price to sales forward of XBiotech Inc. – NASDAQ:XBIT - TradingView
XBiotech, Inc. Actuals & Estimates (BX:4XB) - TradingView
Enterprise value to revenue forward of XBiotech Inc. – NASDAQ:XBIT - TradingView
XBiotech, Inc. Actuals & Estimates (BOATS:XBIT) - TradingView
Price to book forward of XBiotech Inc. – NASDAQ:XBIT - TradingView
XBiotech Inc (XBIT) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
XBiotech to commence V-SPINE trial enrolment for vilamakitug - MSN
XBiotech Inc (XBIT) Financial Health: Profitability & Balance Sheet Analysis - TradingKey
XBiotech Inc (XBIT) Technical Analysis: Support, Resistance, Indicators & Moving Averages - TradingKey
XBiotech Inc (XBIT) Risk Assessment: Volatility, Financial Risk & Investment Risk - TradingKey
XBiotech Inc (XBIT) Valuation: PE, PB & Fair Value Analysis - TradingKey
XBiotech Inc (XBIT) Institutional Confidence - TradingKey
XBiotech Inc (XBIT) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
XBiotech Inc (XBIT) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey
XBiotech Inc (XBIT) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution - TradingKey
XBIT Earnings Overview 2026-06-16Profit Warning Alert - dars.gov.et
XBiotech Receives Authorization for V-SPINE Trial - Intellectia AI
XBiotech Inc Stock (US9840001002): FDA clears Phase II V-SPINE trial for vilamakitug in axial spondy - AD HOC NEWS
XBiotech (XBIT) Receives FDA Nod for V-SPINE Study - GuruFocus
XBiotech clears FDA review for axial spondyloarthritis study - Investing.com
XBiotech Launches Phase II Clinical Trial Evaluating Vilamakitug for the Treatment of Active Axial Spondyloarthritis - Yahoo Finance UK
XBiotech Inc. (XBIT) Holds Near Support Amidst Minor DeclinesDescending Triangle - newsline.com
XBIT Should I Buy - Intellectia AI
XBiotech Inc stock (US9840001002): shares little changed as investors await next earnings update - Ad-hoc-news.de
XBiotech Inc. (XBIT) Slips 2.27% as Stock Tests Key Support LevelsMotive Wave - The Legal Advocate
XBiotech Inc. (XBIT) Edges Higher, Approaching Key Resistance at $2.56Trading Ideas - The Legal Advocate
XBiotech Inc. (XBIT) Edges Higher on Modest Volume, Tests Resistance Near $2.58Composite Profile - The Legal Advocate
XBIT | XBiotech Inc Insider Trading - Quiver Quantitative
XBiotech stock (US9840001002): Clinical-stage biotech stays in focus - AD HOC NEWS
XBiotech: Q1 Earnings Snapshot - Stamford Advocate
XBiotech Inc. Reports Earnings Results for the First Quarter Ended March 31, 2026 - marketscreener.com
XBiotech (NASDAQ: XBIT) trims Q1 2026 loss, holds $115.5M cash and cuts R&D spend - Stock Titan
XBiotech’s New Axial Spondyloarthritis Trial Puts Vilamakitug on Investors’ Radar - TipRanks
TradingKey - TradingKey
Number of shareholders of XBiotech, Inc. – FWB:4XB - TradingView
XBiotech (XBIT) Projected to Post Earnings on Tuesday - MarketBeat
XBIT (XBiotech) reports zero Q1 2020 EPS missing estimates, shares dip 0.78 percent amid investor concern.Post Announcement - newser.com
XBiotech Inc. 2025 Executive Compensation, Board Structure, and Shareholder Ownership Overview - Minichart
Executive pay and governance detailed in XBiotech (NASDAQ: XBIT) 10-K/A - Stock Titan
XBIT Stock: A Comprehensive Guide to XBiotech Inc. - Bitget
XBIT (XBiotech) posts 100 percent Q1 2020 EPS miss, falls 0.79 percent on soft investor sentiment.Trader Community Insights - newser.com
XBIT (XBiotech Inc.) reports 100 percent Q1 2020 EPS miss, while shares notch mild gains on upbeat investor sentiment.Dividend Cut Risk - Xã Thanh Hà
XBiotech (XBIT) Stock: Price Action Overview (Smart Money Active) 2026-04-18Verified Analyst Reports - Xã Vĩnh Công
Short Interest in XBiotech Inc. (NASDAQ:XBIT) Grows By 21.3% - MarketBeat
Aug PostEarnings: Is XBiotech Inc part of any major index2026 Big Picture & Daily Volume Surge Signals - baoquankhu1.vn
Xbiotech Inc Stock (XBIT) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.05%
0.74%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):